Aurobindo Pharma Limited Overview
Pro stress-test →Aurobindo Pharma is a biopharmaceutical company that develops, manufactures, and commercializes generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables across therapeutic areas including CNS, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. The company markets products in over 125 countries with a majority of revenue generated from the United States, making it a critical player in the global generic pharmaceuticals market.
Strategic Profile
Pro stress-test →Aurobindo derives over 70% of its revenues from international operations, primarily from the U.S. The company plans to expand its product portfolio with high-value products in oncology, hormones, biosimilars, and novel drug delivery solutions, while projecting EBITDA margins of 20-21% and over €1 billion revenue from Europe for FY'26.
Competitive Landscape
Pro stress-test →Within the Indian pharmaceutical sector, competitors like Sun Pharma and Dr. Reddy's Laboratories have reported strong results driven by U.S. generics businesses and increasing focus on specialty products. Aurobindo's diversified geographical presence and pipeline development in complex generics and biosimilars position it for continued expansion, offering differentiation through strategic geographic and product diversification.
Industry Context
Aurobindo Pharma Limited operates in Pharmaceuticals - Generic & Specialty.
Key facts
Founded: 1986 · Headquarters: Hyderabad, India · Employees: 40,750 · Revenue: $3.76B · Market cap: $7.1B